Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 52,500 shares, a drop of 69.3% from the September 30th total of 170,900 shares. Based on an average daily trading volume, of 558,600 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.7% of the shares of the company are short sold.
Seelos Therapeutics Trading Up 3.4 %
Shares of SEEL stock traded up $0.04 during trading hours on Friday, hitting $1.22. 14,985 shares of the company’s stock were exchanged, compared to its average volume of 186,307. The firm has a 50 day moving average of $3.38 and a two-hundred day moving average of $14.77. Seelos Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $837.12.
Seelos Therapeutics (NASDAQ:SEEL – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported $1.92 earnings per share for the quarter. The business had revenue of $0.38 million for the quarter.
Institutional Inflows and Outflows
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
Recommended Stories
- Five stocks we like better than Seelos Therapeutics
- How to Start Investing in Real Estate
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Why Invest in 5G? How to Invest in 5G Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.